Advanced search
Publication Cover
Modern Rheumatology Volume 21, 2011 - Issue 2
Journal homepage
16
Views
2
CrossRef citations to date
0
Altmetric
Original Article

Efficacy and safety of single-dose mizoribine for patients with rheumatoid arthritis: results at 6 months after switching from a multiple-dose regimen without a change in total daily dose

Keita NishimuraDepartment of Orthopaedic Surgery, Teikyo University School of Medicine, 2-11-1 Kaga, Itabashi-ku, Tokyo 173-8605, JapanCorrespondence[email protected]
,
Jinju NishinoDepartment of Orthopaedic Surgery, Teikyo University School of Medicine, 2-11-1 Kaga, Itabashi-ku, Tokyo 173-8605, Japan
,
Akira KouchiDepartment of Orthopaedic Surgery, Teikyo University School of Medicine, 2-11-1 Kaga, Itabashi-ku, Tokyo 173-8605, Japan
,
Naotsugu NakamuraDepartment of Orthopaedic Surgery, Teikyo University School of Medicine, 2-11-1 Kaga, Itabashi-ku, Tokyo 173-8605, Japan
,
Shin NakajimaDepartment of Orthopaedic Surgery, Teikyo University School of Medicine, 2-11-1 Kaga, Itabashi-ku, Tokyo 173-8605, Japan
,
Isamu YokoeDivision of Internal Medicine, Itabashi Chuo Medical Center, Tokyo, Japan
,
Hitomi HaraokaDivision of Internal Medicine, Itabashi Chuo Medical Center, Tokyo, Japan
&
Takashi MatsushitaDepartment of Orthopaedic Surgery, Teikyo University School of Medicine, 2-11-1 Kaga, Itabashi-ku, Tokyo 173-8605, Japan
 show all
Pages 158-163 | Received 21 Jul 2010, Accepted 14 Oct 2010, Published online: 02 Jan 2014

References

  • Ishikawa H. Mizoribine and mycophenolate mofetil. Curr Med Chem. 1999;6:575–97.
  • Tsujino M, Ishikawa H, Mizuno K. Effect of mizoribine on adjuvant and collagen arthritis rat (in Japanese). Jpn J Inflamm. 1990;10:63–6.
  • Ishikawa H, Shibata K. Effect of mizoribine on adjuvant arthritis in rat (in Japanese). Jpn J Inflamm. 1991;11:507–11.
  • Saida K, Zhigang Z, Ozawa K, Konishi T, Saida T. Long-term open-trial of mizoribine with prednisolone in 24 patients with multiple sclerosis: safety, clinical and magnetic resonance imaging outcome. Intern Med. 1999;38: 636–42.
  • Shiokawa Y, Honma M, Shichikawa K, Miyamoto T, Hirose J, Nobunaga T, et al. Clinical effectiveness of mizoribine on rheumatoid arthritis: a double-blind comparative study using lobenzarit disodium as a standard drug (in Japanese). Jpn J Inflamm. 1991;11:375–96.
  • Kashiwazaki S, Kondo H, Koike T, Saito T, Kasukawa R, Kashiwagi H, et al. Dose comparison of bredinin on rheumatoid arthritis: a multicenter post-marketing surveillance study (in Japanese). Jpn J Inflamm. 1996;16:269–89.
  • Nishimura K, Itoh K, Kuga Y, Uchida S, Nishino J, Nakamura N, et al. Prevention of joint destruction in rheumatoid arthritis patients receiving combination methotrexate and mizoribine therapy: a two-year, multicenter open-comparison study to methotrexate monotherapy. Prog Med. 2006;26:2163–72.
  • Kuroda T, Hirose S, Tanabe N, Sato H, Nakatsue T, Ajiro J, et al. Mizoribine therapy for patients with lupus nephritis: the associ-ation between peak mizoribine concentration and clinical effi-cacy. Mod Rheumatol. 2007;17:206–12.
  • Yumura K, Uchida K, Kawashima A, Kobayashi H, Miwa N, Honda K, et al. Evaluation of plasma concentration of mizoribine as an immunosuppressive agent in lupus nephritis patients (in Japanese). Kidney Dial. 1999;47:705–8.
  • Irvine S, Cape11 HC. Great expectations of modern RA treatment. Ann Rheum Dis. 2005;64:1249–51.
  • Shida J, Shuto T, Tokito T, Arizono T, Nakashima Y, Okazaki K, et al. Clinical investigation of efficacy by administration of mizoribine once a day for rheumatoid arthritis (in Japanese). Kyushu J Rheumatol. 2006;26:9–14.
  • Tanaka H, Mine T, Tani Y, Sagawa K, Taguchi T. Combination therapy with methotrexate and mizoribine for patients with rheumatoid arthritis (in Japanese). Orthoped Traumatol. 2008;57:439–42.
  • Tokuda M, Dobashi H, Hitaishi T, Mitsunaka H, Takahara J, Hirohata M. Effect of mizoribine pulse therapy on the disease active rheumatoid arthritis refractory to the treatment with methotrexate (in Japanese). Rheumatology. 1998;20:519–26.
  • Murai T, Arai K, Fujisawa J, Ito S. Efficacy and safety of com-bination pulse therapy with methotrexate and mizoribine in rheumatoid arthritis patients (in Japanese). Jpn J Joint Dis. 2009;28:21–7.
  • Horikoshi M, Ito S, Ishikawa M, Umeda N, Kondo Y, Tsuboi H, et al. Efficacy of mizoribine pulse therapy in patients with rheumatoid arthritis who show a reduced or insufficient response to infliximab. Mod Rheumatol. 2009;19:229–34.
  • Kasama T, Wakabayashi K, Odai T, Isozaki T, Matsunawa M, Yajima N, et al. Effects of low-dose mizoribine pulse therapy in combination with methotrexate in rheumatoid arthritis patients with an insufficient response to methotrexate. Mod Rheumatol. 2009;19:395–400.
  • Sonda K, Takahashi K, Tanabe K, Fuchinoue Y, Hayasaka Y, Kawaguchi H, et al. Clinical pharmacokinetic study of mizoribine in renal transplantation patients. Transplant Proc. 1996;28: 3643–8.
  • Mimura T. Disease-modifying antirheumatic drugs. In: Study Group of the Ministry of Health, Labour and Welfare. Thera-peutic manual of rheumatoid arthritis (revised). Diagnostic manual and evidence-based treatment guidelines (in Japanese). Tokyo: Japan Rheumatism Foundation; 2004. p. 84–98.
  • Yamanaka H. Immunosuppressant and biopharmaceuticals. In: Study Group of the Ministry of Health, Labour and Welfare. Therapeutic manual of rheumatoid arthritis (revised). Diagnostic manual and evidence-based treatment guidelines (in Japanese). Tokyo: Japan Rheumatism Foundation; 2004. p. 99–104.
  • Miyasaka N, Takeuchi T, Eguchi K. Official Japanese guideline for the use of infliximab for rheumatoid arthritis. Mod Rheumatol. 2005;15:4–8.
  • Saag KG, Teng GG, Patkar NM, Anuntiyo J, Finney C, Curtis JR, et al. American College of Rheumatology 2008 recommendations for the use of nonbiologic and biologic disease-modifying anti-rheumatic drugs in rheumatoid arthritis. Arthritis Rheum. 2008;59:762–84.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.